Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (91-100 of 399) with videos related to

Pageof 40
Sort By:
Kidney International|August 26, 2004
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetesGuorong Ma, Terri J Allen, Mark E Cooper, et al.
Diabetes & Metabolism|November 1, 2020
Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetesThirunavukkarasu Sathish, Robyn J Tapp, Mark E Cooper, et al.
Seminars in Nephrology|May 14, 2018
Cardiovascular Disease and Diabetic Kidney DiseaseMuhammad Maqbool, Mark E Cooper, Karin A M Jandeleit-Dahm
Current Opinion in Investigational Drugs (London, England : 2000)|October 30, 2003
Diabetes mellitus: a cardiovascular diseaseRiccardo Candido, Piyush Srivastava, Mark E Cooper, et al.
Nature Reviews. Endocrinology|October 9, 2013
Diabetic nephropathy: diagnosis and treatmentDaniel Fineberg, Karin A M Jandeleit-Dahm, Mark E Cooper
Thescientificworldjournal|June 14, 2003
Amylin in the peripheryPeter J Wookey, Loredanna Xuereb, Christos Tikellis, et al.
Seminars in Nephrology|April 10, 2007
AGE, RAGE, and ROS in diabetic nephropathyAdeline L Y Tan, Josephine M Forbes, Mark E Cooper
Current Hypertension Reports|March 8, 2005
Advanced-glycation end products in insulin-resistant statesGeorgia Soldatos, Mark E Cooper, Karin A M Jandeleit-Dahm
Nature Reviews. Nephrology|April 28, 2010
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanismsStephen Tonna, Assam El-Osta, Mark E Cooper, et al.
Experimental Diabetes Research|April 5, 2012
Experimental models of type-2 diabetic nephropathyYasuhiko Tomino, Mark E Cooper, Theodore W Kurtz, et al.
Pageof 40

Showing results (91-100 of 399) with videos related to

Sort By:
Pageof 40
Kidney International|August 26, 2004
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetesGuorong Ma, Terri J Allen, Mark E Cooper, et al.
Diabetes & Metabolism|November 1, 2020
Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetesThirunavukkarasu Sathish, Robyn J Tapp, Mark E Cooper, et al.
Seminars in Nephrology|May 14, 2018
Cardiovascular Disease and Diabetic Kidney DiseaseMuhammad Maqbool, Mark E Cooper, Karin A M Jandeleit-Dahm
Current Opinion in Investigational Drugs (London, England : 2000)|October 30, 2003
Diabetes mellitus: a cardiovascular diseaseRiccardo Candido, Piyush Srivastava, Mark E Cooper, et al.
Nature Reviews. Endocrinology|October 9, 2013
Diabetic nephropathy: diagnosis and treatmentDaniel Fineberg, Karin A M Jandeleit-Dahm, Mark E Cooper
Thescientificworldjournal|June 14, 2003
Amylin in the peripheryPeter J Wookey, Loredanna Xuereb, Christos Tikellis, et al.
Seminars in Nephrology|April 10, 2007
AGE, RAGE, and ROS in diabetic nephropathyAdeline L Y Tan, Josephine M Forbes, Mark E Cooper
Current Hypertension Reports|March 8, 2005
Advanced-glycation end products in insulin-resistant statesGeorgia Soldatos, Mark E Cooper, Karin A M Jandeleit-Dahm
Nature Reviews. Nephrology|April 28, 2010
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanismsStephen Tonna, Assam El-Osta, Mark E Cooper, et al.
Experimental Diabetes Research|April 5, 2012
Experimental models of type-2 diabetic nephropathyYasuhiko Tomino, Mark E Cooper, Theodore W Kurtz, et al.
Pageof 40